Хронический гастрит классификация 2015
Содержание статьи
Helicobacter pylori- // . 2015. No 28. . 16731681.
Helicobacter pylori-: Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P.
Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P. Kyoto global consensus report on Helicobacter pylori gastritis // Gut 2015;64:1353-1367. . , , . () , , . Helicobacter pylori (H. pylori) , . H. pylori. , 12- , MALT- [35]. , H. pylori , [5]. H. pylori- , , 4 : ICD (); H. pylori-; . . 1. ICD-11 ICD-10 ? 1 ICD-10 H. pylori.
ICD-10 1989 . . ICD-10 , ; [6] (. 1).
, [1]. H. pylori , [2, 24, 25]. H. pylori . ICD-10 ? 2 ICD-11 β , .
ICD-10 ( , (International istical Classification of Diseases and Health Problems) , . . . ICD11 β- ICD-11 (https:// www .who.int/classifications/icd/revision/betaexpectations/en/). ICD-11-β , . , H. pylori- . , , H. pylori . , . , , , , , [19, 20]. ICD-11 β- , 3 : (a) H. pylori-, (b) — (c) . H. pylori- [26, 27] , . H. pylori H. pylori [5, 11, 28]. H. pylori , H. pylori- [29]. , , ICD-11 β- , (. 2). .
? 3 H. pylori- , .
H. pylori- , . . [3032]. , , [3335]. ( ) [31, 37], . () / ? 4 , H. pylori- .
H. pylori- , [19, 20]. [31, 39, 40]. , H. pylori- [31, 41]. . (OLGA) (OLGIM) [16, 17]. ? 5 . .
3 5 [42]. , , [3]. H. pylori , , () [43, 44]. , , , [48]. , , [49]. H. pylori- , ? 6 H. pylori- , , , .
H. pylori- , [50]. , [30, 35]. H. pylori- , . H. pylori . H. pylori (). H. pylori- , , , , , [5, 11, 28, 31, 36, 40]. 2. , H. pylori H. pylori- ? 7 H. pylori- .
: H. pylori [26, 27]. -, H. pylori [24, 25], [48]. -, , H. pylori [5255]. . NNT* 14 [12, 5661], 8 [61]. 6 . (, ), , [12, 5961]. H. pylori- ? 8A , H. pylori, H. pylori- , .
8B H. pylori- ( 8A) .
III [9, 62] ( , , ) ( ) , ( 1). , [9]. III H. pylori- , . H. pylori- H. pylori [9]. , , , H. pylori- , 6 . [12, 5961]. H. pylori H. pylori- . H. pylori- , 1. H. pylori ? 9 H. pylori H. pylori- .
8, H. pylori . [9, 5961], [12, 5961]. , , [5]. , H. pylori, [64]. H. pylori , ( ())? 10 , H. pylori, , , .
, , , , H. pylori , [12, 5661]. . , H. pylori, , ? 11 , H. pylori, .
8A 8B III [9, 62], H. pylori- H. pylori- . : , , H. pylori- . , ( 1).
1. H. pylori- , H. pylori , 3. / ? 12 , .
, , , , [19, 20]. . : [65], c [66, 67] , [15, 6872] ( 2). . [66] . 2. . . (NBI) . (). . blue laser imaging ? 13 , .
, [20, 7376]. 5 : , , [36]. , . , , [66, 77, 78]. , OLGA OLGIM, ? 14A .
14B , OLGA OLGIM, .
, H. pylori : , / . . , , , 98 000 , 23% 10 [79]. , 0,8, 1,8, 3,9 32,7% , , [79]. , . , , — (26 1000 ). . . OLGA [16, 17], [8082]. OLGIM, [18]. OLGA OLGIM III IV OLGA OLGIM [8284]. . ( I, II, I/II, H. pylori) ? 15 ( I, II H. pylori) .
25 . H. pylori , I, II , [85]. , [86, 87]. , 9293 , I, II H. pylori [86]. , H. pylori. (3,56 1000 ) , [86]. H. pylori . . [88, 89]. H. pylori- ? 16 H. pylori- .
H. pylori 12 , [9092]. , . [31, 8284, 86]. H. pylori , [9395]. H. pylori , . 10 H. pylori [96]. H. pylori- , (>12 ) . , [97]. H. pylori ? 17 H. pylori- , .
H. pylori , , , . MALT- , , [5, 12, 46, 47, 61, 98104]. H. pylori- . H. pylori , , , . , , . , , , , , H. ylori- , — , H. ylori- [2, 5, 11, 28, 46, 47, 106115]. , , , , , H. ylori- , . , , H. pylori, , , , , , . , , , [116, 117]. H. pylori ? 18 H. pylori , .
H. pylori , . H. ylori . , , . H. pylori , . , , , . H. pylori H. ylori- . [118], [119], (AICDA), , [120], , , , — , — CpG [121123] [124]. (, Cag). , . , H. pylori . H. pylori . ? 19 , .
H. pylori [125], . . , 90% , [5, 126129]. H. pylori ? 20 H. pylori . , .
, H. ylori, , , 89% , 78% [130]. H. pylori , , . H. pylori [94, 95]. 3, , , (OLGA OLGIM) [1618]. , H. pylori [28, 94]. H. pylori . , [5, 71, 72, 77, 131]. , [132]. (. . )? 21 , .
, , , [5]. , , , , , . , [125, 128, 129]. ? 22 H. pylori . , , .
H. pylori (. . ) [95, 133]. , OLGA. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P. Kyoto global consensus report on Helicobacter pylori gastritis // Gut 2015;64:1353-1367. «». : » «, » -«, » «, » » . | ||||||||||||||||||||||||||||||||||||||
Helicobacter pylori- .
Источник
Киотский глобальный консенсус по Helicobacter pylori-ассоциированному гастриту
1. Strickland RG. Gastritis. Front Gastrointest Res 1975;1:12-48. doi:10.1159/000395803 [PubMed]
2. Marshall BJ, Warren JR Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;323:1311-15. doi:10.1016/S0140-6736(84)91816-6 [PubMed]
3. Malfertheiner P, Chan FK, McColl KE Peptic ulcer disease. Lancet 2009;374:1449-61.doi:10.1016/S0140-6736(09)60938- [PubMed]
4. Fock KM, Graham DY, Malfertheiner P Helicobacter pylori re: historical insights and future directions. Nat Rev Gastroenterol Hepatol 2013;10:495-500. doi:10.1038/nrgastro.2013.96[PMC free article] [PubMed]
5. Malfertheiner P, Mégraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV Florence Consensus Report. Gut 2012;61:646-64. doi:10.1136/gutjnl-2012-302084 [PubMed]
6. https://apps.who.int/classifications/icd10/browse/2015/en#/K29 (20 January 2015).
7. Sugano K. Should we still subcategorize Helicobacter pylori-associated dyspepsia as al disease? J Neurogastroenterol Motil 2011;17:366-71. doi:10.5056/jnm.2011.17.4.366 [PMC free article] [PubMed]
8. Suzuki H, Nishizawa T, Hibi T Can Helicobacter pylori-associated dyspepsia be categorized as al dyspepsia? J Gastroenterol Hepatol 2011;26(Suppl 3):42-5. doi:10.1111/j.1440-1746.2011.06629.x[PubMed]
9. Tack J, Talley N, Camilleri M, et al. al gastrodudenal disorders. In Drossman DA, Corazziari F, Delvaux M, et al. eds Rome III: the al gastrointestinal disorders. 3rd edn McLean, VA: Denon Associates, Inc, 2006:419-86.
10. Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on al dyspepsia. J Gastroenterol Hepatol 2012;27:626-41. doi:10.1111/j.1440-1746.2011.07037.x [PubMed]
11. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20. doi:10.1111/j.1523-5378.2009.00738.x [PubMed]
12. Moayyedi P, Soo S, Deeks JJ, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia.Cochrane Database Syst Rev 2011;16(2):CD002096. [PubMed]
13. Yagi K, Nakamura A, Sekine A Characteristic endoscopic and magnified endoscopic findings in the normal stomach without Helicobacter pylori infection. J Gastroenterol Hepatol 2002;17:39-45.doi:10.1046/j.1440-1746.2002.02665.x [PubMed]
14. Yagi K, Nakamura A, Sekine A Comparison between magnification endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. Endoscopy 2002;24:376-81. doi:10.1055/s-2002-25281 [PubMed]
15. Okubo M, Tahara T, Shibata T, et al. Usefulness of magnifying narrow-band imaging endoscopy in theHelicobacter pylori-associated chronic gastritis. Digestion 2011;83:161-6. doi:10.1159/000321799[PubMed]
16. Rugge M, Genta RM Staging and grading of chronic gastritis. Hum Pathol 2005;36:228-33.doi:10.1016/j.humpath.2004.12.008 [PubMed]
17. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liv Dis 2008;40:650-8. doi:10.1016/j.dld.2008.02.030 [PubMed]
18. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal plasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-8.doi:10.1016/j.gie.2009.12.029 [PubMed]
19. Price AB. The Sydney system: histological division. J Gastroenterol Hepatol 1991;6:209-22.doi:10.1111/j.1440-1746.1991.tb01468.x [PubMed]
20. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The upd Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol1996;20:1161-81. doi:10.1097/00000478-199610000-00001 [PubMed]
21. Quaseem A, Snow V, Owens DK, et al. The development of Clinical Practice guidelines and guidance ement of the American College of Physicians: summary of methods. Ann Intern Med 2010;153:194-9.doi:10.7326/0003-4819-153-3-201008030-00010 [PubMed]
22. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of ations. BMJ2004;328:1490 doi:10.1136/bmj.328.7454.1490 [PMC free article] [PubMed]
23. Jones DJ, Barkun AN, Lu Y, et al. Conflicts of interest ethics; silencing expertise in the development of international practice guidelines. Ann Intern Med 2012;56:809-16. doi:10.7326/0003-4819-156-11-201206050-00008 [PubMed]
24. Marshall BJ, Armstrong JA, McGechie DB, et al. Attempt to fulfil Koch’s postulates for pyloricCampylobacter. Med J Aust 1985;142:436-9. [PubMed]
25. Morris A, Nicholson G Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987;82:192-9. [PubMed]
26. Buckley M, O’Morain C Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Aliment Pharmacol Ther 1995;9(Suppl 2):53-8. [PubMed]
27. Rosenstock S, Kay L, Rosenstock C, et al. Relation between Helicobacter pylori infection and gastrointestinal symptoms and syndromes. Gut 1997;41:169-76. doi:10.1136/gut.41.2.169 [PMC free article][PubMed]
28. Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a e-of-the-art critique. Am J Gastroenterol 2005;100:2100-15. doi:10.1111/j.1572-0241.2005.41688.x [PubMed]
29. Nordenstedt H, Graham DY, Kramer JR, et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol 2013;108:65-71. doi:10.1038/ajg.2012.372 [PMC free article] [PubMed]
30. Meining A, Stolte M, Hatz R, et al. Differing degree and distribution of gastritis in Helicobacter pylori-associated diseases. Virchows Arch 1997;431:11-15. doi:10.1007/s004280050063 [PubMed]
31. Uemura N, Okamoto S, Yamamoto S, et al. H. pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9. doi:10.1056/NEJMoa001999 [PubMed]
32. Sipponen M, Kosunen TU, Valle J, et al. H. pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 1992;45:319-23. doi:10.1136/jcp.45.4.319 [PMC free article] [PubMed]
33. El-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995;109:681-91. doi:10.1016/0016-5085(95)90374-7 [PubMed]
34. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24. doi:10.1016/S0016-5085(97)70075-1 [PubMed]
35. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011;29:459-64. doi:10.1159/000332213 [PubMed]
36. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP) and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-94. doi:10.1055/s-0031-1291491 [PMC free article][PubMed]
37. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am 2013;42:211-17.doi:10.1016/j.gtc.2013.01.002 [PMC free article] [PubMed]
38. Tanaka A, Kamada T, Inoue K, et al. Histological evaluation of patients with gastritis at high risk of developing gastric cancer using a conventional index. Pathol Res Pract 2011;207:354-8.doi:10.1016/j.prp.2011.03.001 [PubMed]
39. Meining A, Bayerdörffer E, Müller P, et al. Gastric carcinoma risk index in patients infected withHelicobacter pylori. Virchows Arch 1998;432:311-14. doi:10.1007/s004280050171 [PubMed]
40. Naylor GM, Gotoda T, Dixon M, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 2006;55:1545-52.doi:10.1136/gut.2005.080358 [PMC free article] [PubMed]
41. Miehlke S, Hackelsberger A, Meining A, et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998;78:263-6.doi:10.1038/bjc.1998.475 [PMC free article] [PubMed]
42. Yeomans ND, Naesdal J Systematic Review: ulcer definition in NSAID ulcer prevention. Aliment Pharamcol Ther 2008;27:465-72. doi:10.1111/j.1365-2036.2008.03610.x [PubMed]
43. Toljamo K, Niemelä S, Karvonen AL, et al. Histopathology of gastric erosions. Association with etiological factors and chronicity. Helicobacter 2011;16: 444-51. doi:10.1111/j.1523-5378.2011.00871.x[PubMed]
44. Hart J, Hawkey CJ, Lanas A, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther 2010;31:143-9. doi:10.1111/j.1365-2036.2009.04133.x [PubMed]
45. Kato M, Terao S, Adachi K, et al. Changes in endoscopic findings of gastritis after cure of H. pyloriinfection: multicenter prospective trial. Dig Endosc 2013;25:264-73. doi:10.1111/j.1443-1661.2012.01385.x[PubMed]
46. Annibale B, Sprile MR, D’ambra G, et al. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 2000;14:625-34. doi:10.1046/j.1365-2036.2000.00752.x[PubMed]
47. Iijima K, Ohara S, Sekine H, et al. Changes in gastric secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut 2000;46:20-6. doi:10.1136/gut.46.1.20 [PMC free article][PubMed]
48. Hawkey CJ, Wilson I, Naesdal J, et al. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 2002;51:344-50.doi:10.1136/gut.51.3.344 [PMC free article] [PubMed]
49. Lanza FL, Evans DG, Graham DY Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers. Am J Gastroenterol 1991;86:735-7. [PubMed]
50. Sonnenberg A, Lash RH, Genta RM A national study of Helicobacter pylori infection in gastric biopsy specimens. Gastroenterology 2010;139:1894-901. doi:10.1053/j.gastro.2010.08.018 [PubMed]
51. Graham DY, Opekun AR, Osato MS, et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004;53:1235-43. doi:10.1136/gut.2003.037499 [PMC free article] [PubMed]
52. Bode G, Brenner H, Adler G, et al. Dyspeptic symptoms in middle-aged to old adults: the role ofHelicobacter pylori infection and various demographic and lifestyle factors. J Intern Med 2002;252:41-7.doi:10.1046/j.1365-2796.2002.01000.x [PubMed]
53. Moayyedi P, Forman D, Braunholtz D, et al. The proportion of upper gastrointestinal symptoms in the associated with Helicobacter pylori, lifestyle factors and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group. Am J Gastroenterol 2000;95:1448-55. doi:10.1111/j.1572-0241.2000.2126_1.x[PubMed]
54. Wildner-Christensen M, Hansen JM, De Muckadell OB Risk factors for dyspepsia in a general population: non-steroidal anti-inflammatory drugs, cigarette smoking and unemployment are more important than Helicobacter pylori infection. Scand J Gastroenterol 2006;41:149-54.doi:10.1080/00365520510024070 [PubMed]
55. Nandurkar S, Talley NJ, Xia H, et al. Dyspepsia in the is ed to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med 1998;158:1427-33.doi:10.1001/archinte.158.13.1427 [PubMed]
56. Makris N, Barkun A, Crott R, et al. Cost-effectiveness of alternative approaches in the management of dyspepsia. Int J Technol Assess Health Care 2003;19:446-64. [PubMed]
57. Ang T, Fock KM, Teo EK, et al. Helicobacter pylori eradication versus prokinetics in the treatment of al dyspepsia: a randomized, double-blind study. J Gastroenterol 2006;41:647-53.doi:10.1007/s00535-006-1818-x [PubMed]
58. Delaney B, Ford AC, Forman D, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2009;7:CD001961. [PubMed]
59. Suzuki H, Moayyedi P Helicobacter pylori infection in al dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:168-74. doi:10.1038/nrgastro.2013.9 [PubMed]
60. Malfertheiner P, Mossner J, Fischbach W, et al. Helicobacter pylori eradication is beneficial in the treatment of al dyspepsia. Aliment Pharmacol Ther 2003;18:615-25. doi:10.1046/j.1365-2036.2003.01695.x [PubMed]
61. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in al dyspepsia: HEROES trial. Arch Intern Med 2011;171:1929-36. doi:10.1001/archinternmed.2011.533[PubMed]
62. Tack J, Talley NJ, Camilleri M, et al. al gastroduodenal disorders. Gastroenterology2006;130:1466-79. doi:10.1053/j.gastro.2005.11.059 [PubMed]
63. Camilleri M, Stanghellini V Current management strategies and emerging treatments for al dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:187-94. doi:10.1038/nrgastro.2013.11 [PubMed]
64. Tack J, Talley NJ Gastroduodenal disorders. Am J Gastroenterol 2010;105:757-63.doi:10.1038/ajg.2010.66 [PubMed]
65. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal plasia and dysplasia. Gastrointest Endosc 2003;57:498-504.doi:10.1067/mge.2003.145 [PubMed]
66. Anagnostopoulos GK, Yao K, Kaye P, et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis and gastric atrophy. Endoscopy2007;39:202-7. doi:10.1055/s-2006-945056 [PubMed]
67. Gonen C, Simsek I, Sarioglu S, et al. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study. Helicobacter 2009;14:12-21. doi:10.1111/j.1523-5378.2009.00650.x [PubMed]
68. Uedo N, Ishihara R, Iishi H, et al. A new method of diagnosing gastric intestinal plasia: narrow-band imaging with magnifying endoscopy. Endoscopy 2006;38:819-24. doi:10.1055/s-2006-944632[PubMed]
69. Tahara T, Shibata T, Nakamura M, et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc 2009;70:246-53. doi:10.1016/j.gie.2008.11.046 [PubMed]
70. Kato M, Kaise M, Yonezawa J, et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 2010;72:523-9. doi:10.1016/j.gie.2010.04.041[PubMed]
71. Capelle LG, Haringsma J, de Vries AC, et al. Narrow band imaging for the detection of gastric intestinal plasia and dysplasia during surveillance endoscopy. Dig Dis Sci 2010;55:3442-8. doi:10.1007/s10620-010-1189-2 [PMC free article] [PubMed]
72. Osawa H, Yamamoto H, Miura Y, et al. Blue laser imaging provides excellent endsocopic images of upper gastrointestinal lesions. Video J Encyclopedia of GI endoscopy 2014;1:607-10.doi:10.1016/j.vjgien.2014.01.001
73. Lim JH, Kim N, Lee HS, et al. Correlation between endoscopic and histological diagnoses of gastric intestinal plasia. Gut Liver 2013;7:41-50. doi:10.5009/gnl.2013.7.1.41 [PMC free article] [PubMed]
74. de Vries AC, Haringsma J, de Vries RA, et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 2010;15:259-64. doi:10.1111/j.1523-5378.2010.00760.x [PubMed]
75. El-Zimaity HM, Graham DY Evaluation of gastric mucosal biopsy site and number for identification ofHelicobacter pylori or intestinal plasia: role of the Sydney System. Hum Pathol 1999;30:72-7.doi:10.1016/S0046-8177(99)90303-9 [PubMed]
76. Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pyloriinfection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 1998;93:569-73.doi:10.1111/j.1572-0241.1998.166_b.x [PubMed]
77. Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB, et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. Endsocopy2012;44:236-46. doi:10.1055/s-0031-1291537 [PubMed]
78. Kikuste I, Stirna D, Liepniece-Karele I, et al. The accuracy of flexible spectral imaging colour enhancement for the diagnosis of gastric intestinal plasia: do we still need histology to select individuals at risk of adenocarcinoma? Eur J Gastroenterol Hepatol 2014;26:704-9.doi:10.1097/MEG.0000000000000108 [PubMed]
79. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945-52.doi:10.1053/j.gastro.2008.01.071 [PubMed]
80. Rugge M, Kim JG, Mahachai V, et al. OLGA gastritis staging in young adults and country-specific gastric cancer risk. Int J Surg Pathol 2008;16:150-4. doi:10.1177/1066896907307238 [PubMed]
81. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system.Gut 2007;l56:631-6. doi:10.1136/gut.2006.106666 [PMC free article] [PubMed]
82. Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010;31:1104-11. [PubMed]
83. den Hoed CM, Holster IL, Capelle LG, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy 2013;45:249-56. doi:10.1055/s-0032-1326379 [PubMed]
84. Rugge M, Fassan M, Pizzi M, et al. Operative for gastritis assessment vs operative on intestinal plasia assessment. World J Gastroenterol 2011;17:4596-601. doi:10.3748/wjg.v17.i41.4596[PMC free article] [PubMed]
85. Kuipers EJ. In through the out door: serology for atrophic gastritis. Eur J Gastroenterol Hepatol2003;15:877-9. doi:10.1097/00042737-200308000-00007 [PubMed]
86. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combiningHelicobacter pylori antibodies and serum pepsinogen us: a prospective endoscopic cohort study. Gut2005;54:764-8. doi:10.1136/gut.2004.055400 [PMC free article] [PubMed]
87. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-«ABC method». Proc Jpn Acad SerB Phys Biol Sci 2011;87:405-14.doi:10.2183/pjab.87.405 [PMC free article] [PubMed]
88. Broutet N, Plebani M, Sakarovitch C, et al. Pepsinogen A, pepsinogen C and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer 2003;88:1239-47. doi:10.1038/sj.bjc.6600877[PMC free article] [PubMed]
89. Agreus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47:136-47.doi:10.3109/00365521.2011.645501 [PMC free article] [PubMed]
90. Okuda M, Nakazawa T, Booka M, et al. Evaluation of a urine antibody test for Helicobacter pylori in Japanese children. J Pediatr 2004;144:196-9. doi:10.1016/j.jpeds.2003.10.057 [PubMed]
91. Okuda M, Sugiyama T, Fukunaga K, et al. A strain-specific antigen in Japanese Helicobacter pylorirecognized in sera of Japanese children. Clin Diagn Lab Immunol 2005;12:1280-4. [PMC free article][PubMed]
92. Mégraud F., European Paediatric Task Force on Helicobacter pylori. Comparison of non-invasive tests to detect Helicobacter pylori infection in children and adolescents: results of a multicenter European study. J Pediatr 2005;146:198-203. doi:10.1016/j.jpeds.2004.10.044 [PubMed]
93. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and -analysis of randomised controlled trials. BMJ 2014;348:g3174 doi:10.1136/bmj.g3174 [PMC free article] [PubMed]
94. Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 2007;42(Suppl 7):21-7. doi:10.1007/s00535-006-1924-9 [PubMed]
95. Chen HN, Wang Z, Li X, et al. Helicobacter pylori eradication cannot reduce the risk of Gastric Cancer in patients with intestinal plasia and dysplasia: evidence from a -analysis. Gastric Cancer Online First: 22 Jan 2015. doi:10.1007/s10120-015-0462-7 doi:10.1007/s10120-015-0462-7 [PubMed]
96. de Vries AC, Kuipers EJ, Rauws EA Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009;104: 1342-5. doi:10.1038/ajg.2008.15 [PubMed]
97. Zhang YY, Xia HH, Zhuang ZH, et al. Review article: ‘true’ re-infection of Helicobacter pylori after successful eradication—worldwide annual rates, risk factors and clinical implications. Aliment Pharmacol Ther 2009;29:145-60. doi:10.1111/j.1365-2036.2008.03873.x [PubMed]
98. Franchini M, Vescovi PP, Garofano M, et al. Helicobacter pylori-associated idiopathic thrombocytopenic purpura: a narrative review. Semin in Thromb Hemost 2012;38:463-8. doi:10.1055/s-0032-1305781[PubMed]
99. Franchini M, Cruciani M, Mengoli C, et al. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and -analysis. J Antimicrob Chemother2007;60:237-46. doi:10.1093/jac/dkm195 [PubMed]
100. Harvey RF, Lane JA, Nair P, et al. Clinical trial: prolonged beneficial effect of Helicobacter pylorieradication on dyspepsia consultations-the Bristol Helicobacter Project. Aliment Pharmacol Ther2010;32:394-400. doi:10.1111/j.1365-2036.2010.04363.x [PubMed]
101. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ2000;162:S3-23. [PMC free article] [PubMed]
102. Ohkusa T, Takashimizu I, Fujiki K, et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann Intern Med 1998;129:712-15.[PubMed]
103. Suzuki H, Saito Y, Hibi T Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: upd review of clinical outcomes and the molecular pathogenesis. Gut Liver2009;3:81-7. doi:10.5009/gnl.2009.3.2.81 [PMC free article] [PubMed]
104. Du MQ, Diss TC, Dogan A, et al. Clone-specific PCR reveals wide dissemination of gastric MALT lymphoma to the gastric mucosa. J Pathol 2000;192: 488-93. doi:10.1002/1096-9896(2000)9999:9999<::AID-PATH727>3.0.CO;2-J [PubMed]
105. Clark EG, Danbolt N The Oslo study of the natural course of untreated syphilis. An epidemiologic investigation based on re-study of the Boeck-Burrsgaard material. Med Clin North Am 1964;48:613-23.
106. Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997;32:664-8.doi:10.3109/00365529708996515 [PubMed]
107. Gisbert JP, Khorrami S, Carballo F, et al. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004;(2):CD004062. [PubMed]
108. Vergara M, Catalan M, Gisbert JP, et al. -analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-18. doi:10.1111/j.1365-2036.2005.02444.x [PubMed]
109. Genta RM, Lew GM, Graham DY Changes in gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 1993;6:281-9. [PubMed]
110. Franceschi F, Genta RM, Sepulveda AR Gastric mucosa: long-term outcome after cure of Helicobacter pylori infection. J Gastroenterol 2002;37(Suppl 13):17-23. doi:10.1007/BF02990094 [PubMed]
111. Graham DY, Shiotani A, El-Zimaity HM Chromoendoscopy points the way to understanding recovery of gastric after Helicobacter pylori eradication. Gastrointest Endosc 2006;64:686-9.doi:10.1016/j.gie.2006.03.013 [PubMed]
112. Graham DY. Helicobacter pylori and perturbations in acid secretion: the end of the beginning [editorial]. Gastroenterology 1996;110:1647-50. doi:10.1053/gast.1996.v110.agast961647 [PubMed]
113. Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol Ther1999;13:155-62. doi:10.1046/j.1365-2036.1999.00459.x [PubMed]
114. Yasunaga Y, Shinomura Y, Kanayama S, et al. Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis. Gut 1994;35:1571-4.doi:10.1136/gut.35.11.1571 [PMC free article] [PubMed]
115. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a -based study of gastric cancer prevention. Gut 2013;62:676-82. doi:10.1136/gutjnl-2012-302240[PMC free article] [PubMed]
116. Atherton JC, Blaser MJ Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009;119:2475-87. doi:10.1172/JCI38605 [PMC free article] [PubMed]
117. Dorer MS, Talarico S, Salama NR Helicobacter pylori’s unconventional role in health and disease.PLoS Pathog 2009;5:e1000544 doi:10.1371/journal.ppat.1000544 [PMC free article] [PubMed]
118. Toller IM, Neelsen KJ, Steger M, et al. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc Natl Acad Sci2011;108:14944-9. doi:10.1073/pnas.1100959108 [PMC free article] [PubMed]
119. Kim JJ, Tao H, Carloni E, et al. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology 2002;123:542-53. doi:10.1053/gast.2002.34751 [PubMed]
120. Matsumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007;13:470-6.doi:10.1038/nm1566 [PubMed]
121. Shin CM, Kim N, Jung Y, et al. Genome-wide DNA methylation profiles in noncancerous gastric mucosae with regard to Helicobacter pylori infection and the presence of gastric cancer. Helicobacter2011;16:179-88. doi:10.1111/j.1523-5378.2011.00838.x [PubMed]
122. Ushijima T, Hattori N Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect and its usefulness as cancer risk and exposure markers. Clin Cancer Res 2012;18:923-9. doi:10.1158/1078-0432.CCR-11-2011 [PubMed]
123. Zabaleta J. MicroRNA: a bridge from H. pylori infection to gastritis and gastric cancer development.Front Genet 2012;3:294 doi:10.3389/fgene.2012.00294 [PMC free article] [PubMed]
124. Nishizawa T, Suzuki H The role of microRNA in gastric malignancy. Int J Mol Sci 2013;14:9487-96.doi:10.3390/ijms14059487 [PMC free article] [PubMed]
125. Mégraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42. doi:10.1136/gutjnl-2012-302254 [PubMed]
126. Furuta T, Graham DY Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.Gastroenterol Clin North Am 2010;39:465-80. doi:10.1016/j.gtc.2010.08.007 [PubMed]
127. Graham DY, Shiotani A Which therapy for Helicobacter pylori infection? Gastroenterology2012;143:10-12. doi:10.1053/j.gastro.2012.05.012 [PMC free article] [PubMed]
128. Graham DY, Lee YC, Wu MS Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86. doi:10.1016/j.cgh.2013.05.028[PMC free article] [PubMed]
129. Wu JY, Liou JM, Graham DY Evidence-based ations for successful Helicobacter pyloritreatment. Expert Rev Gastroenterol Hepatol 2014;8:21-8. doi:10.1586/17474124.2014.859522 [PubMed]
130. International Agency for Re on Cancer. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC Working Group Reports Vol 8, WHO Press, World Health Organization, Geneva, Switzerland, 2014.
131. Shiotani A, Cen P, Graham DY Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013;23:492-501. doi:10.1016/j.semcancer.2013.07.004 [PubMed]
132. Matsueda S, Graham DY Immunotherapy in gastric cancer. World J Gastroenterol 2014;20:1657-66.doi:10.3748/wjg.v20.i7.1657 [PMC free article] [PubMed]
133. Graham DY, Shiotani A The to eradicate gastric cancer is now. Gut 2005;54:735-8.doi:10.1136/gut.2004.056549 [PMC free article] [PubMed]
134. Kimura K, Satoh K, Ido K, et al. Gastritis in the Japanese stomach. Scand J Gastroenterol1996;31(Suppl 214):17-20. doi:10.3109/00365529609094509 [PubMed]
135. Kimura K, Takemoto T An endoscopic recognition of the atrophic border and its ificance in chronic gastritis. Endoscopy 1969;1:87-97. doi:10.1055/s-0028-1098086
136. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006;9:245-53. doi:10.1007/s10120-006-0397-0 [PubMed]
137. Dinis-Ribeiro M, Yamaki G, Miki K, et al. -analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141-7.doi:10.1258/0969141041732184 [PubMed]
138. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal plasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia 2004;6:449-56. doi:10.1593/neo.03505 [PMC free article][PubMed]
139. Schindler R. Chronic gastritis. Bull NY Acad Med 1939;15:322-37. [PMC free article] [PubMed]
140. Lau JY, Barkun A, Fan DM, et al. Challenges in the management of acute peptic ulcer bleeding. Lancet2013;381:2033-43. doi:10.1016/S0140-6736(13)60596-6 [PubMed]
141. Jőnsson KA, Gotthard R, Bodemar G, et al. The clinical relevance of endoscopic and histologic inflammation of gastroduodenal mucosa in dyspepsia of unknown origin. Scand J Gastroenterol1989;24:385-95. doi:10.3109/00365528909093064 [PubMed]
142. Talley N, Phillips SF Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med1988;108:865-79. doi:10.7326/0003-4819-108-6-865 [PubMed]
143. Lambert JR. The role of Helicobacter pylori in nonulcer dyspepsia. A debate-for. Gastroenterol Clin North Am 1993;22:141-51. [PubMed]
144. Talley NJ. The role of Helicobacter pylori in nonulcer dyspepsia. A debate-against. Gastroenterol Clin North Am 1993;22:153-67. [PubMed]
Источник